News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech

Advertisement

BEGIN ARTICLE PREVIEW:

The transat­lantic biotech ADC Ther­a­peu­tics is get­ting a speedy re­view for its an­ti-body drug con­ju­gate lon­cas­tux­imab tesirine (Lon­ca), de­vel­oped for re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma.
Chris Mar­tin ADC
ADC $AD­CT said Fri­day morn­ing that the FDA put their drug on the fast lane, pro­vid­ing a pri­or­i­ty re­view for the drug with a May 21 PDU­FA date. The biotech won over reg­u­la­tors with Phase II da­ta that re­flect­ed an over­all re­sponse rate of 48.3% (70/145 pa­tients) and a com­plete re­sponse rate of 24.1%.
“The FDA’s ac­cep­tance of our BLA and grant­i­ng of pri­or­i­ty re­view for Lon­ca is a tremen­dous ac­com­plish­ment that brings ADC Ther­a­peu­tics one step clos­er to be­ing able to of­fer pa­tients with re­lapsed or re­frac­to­ry DL­B­CL a great­ly need­ed new treat­ment op­tion in 2021,” said ADC chief Chris …

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE